Vor Biopharma Inc. 8-K

What Happened
Vor Biopharma Inc. (VOR) filed an 8‑K on January 12, 2026 to disclose preliminary year‑end financial information and to furnish its presentation for the 44th Annual J.P. Morgan Healthcare Conference. The company reported that as of December 31, 2025, its cash, cash equivalents and short‑term investments were approximately $450 million. The company noted this figure is preliminary, unaudited and subject to change upon completion of the audited 2025 financial statements; the independent auditor has not audited or reviewed this estimate. The presentation is attached as Exhibit 99.1.

Key Details

• Preliminary cash, cash equivalents and short‑term investments: approximately $450 million (as of 12/31/2025).
• Disclosure date / filing: January 12, 2026 (Form 8‑K, Item 2.02 and Item 7.01).
• JP Morgan presentation: scheduled Jan 13, 2026, 10:30–11:10 AM PT at The Westin St. Francis (Georgian Room); presentation is available on the company website and filed as Exhibit 99.1.
• Company cautioned additional disclosures will be needed for a complete financial picture; independent auditor has not provided assurance on the preliminary estimate.

Why It Matters
Cash and short‑term investments are key indicators of a biotech company's ability to fund operations, clinical programs and development milestones without immediate financing. Investors can use this preliminary $450M figure to gauge Vor’s near‑term financial flexibility, but should note the number is unaudited and may change when audited 2025 results are released. The JP Morgan presentation may provide additional context on strategy and programs; any material updates will typically be reflected in future SEC filings.